Torrent Pharmaceuticals revenue and financials

500420 · BSE · INR

₹4,710.00−1.42%−₹68.00

Close · October 7, 2026

In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹139.8B (+21.39% year over year). Net income was ₹21.63B, a net margin of 15.5%.

Annual revenue · 2026: ₹139.8B
  1. ₹85.08B2022
  2. ₹96.2B2023
  3. ₹107.28B2024
  4. ₹115.16B2025
  5. ₹139.8B2026

Fiscal year ending in March. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+21.39%
FY to Mar 2026 vs FY to Mar 2025
Net income growth
+13.19%
FY to Mar 2026 vs FY to Mar 2025
Net margin
15.5%
FY to Mar 2025: 16.6%

Financial data

Amounts in millions of INR; per-share values in INR; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets—443,120—155,150—149,897—150,880—150,606—147,440
Current assets—93,931—61,920—56,226—58,790—56,115—52,870
Cash and equivalents—11,172—7,050—5,735—11,500—8,351—5,560
Short-term investments—3,723—890—22.8—850—279—2,340
Receivables—36,846—21,900—22,480—17,870—21,863—17,550
Inventory—31,382—24,670—25,413—22,710—22,791—22,180
Net property, plant and equipment—53,660—39,460—38,229—36,290—35,778—34,550
Goodwill—39,896—3,400—3,389—3,390—3,380—3,370
Other intangible assets—244,636—40,430—42,633—43,340—45,828—48,400
Long-term investments—994—440—446—420—333—430
Current liabilities—83,433—44,350—47,172—48,470—54,253—48,980
Accounts payable—23,576—16,750—18,200—21,880—20,893—16,610
Long-term debt—116,512—10,450—11,918—14,140—16,038—21,100
Total debt—150,255—28,220—32,023——————
Total liabilities—267,271—70,660—73,991—75,840—82,044—80,370
Total equity (incl. minority)175,848175,84884,49084,49075,90775,90775,04075,04068,56268,56267,07067,070
Retained earnings—86,439———76,307———67,908——
Minority interest—91,964———0.0——————